{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T11:55:24Z","timestamp":1778414124405,"version":"3.51.4"},"reference-count":45,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T00:00:00Z","timestamp":1610582400000},"content-version":"unspecified","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2020,12,30]]},"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This post-hoc analysis explored the impact of body mass index (BMI) on tofacitinib efficacy\/safety in patients with active psoriatic arthritis (PsA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Data were pooled from two phase 3 studies (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01877668\">NCT01877668<\/jats:ext-link>;  <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT01882439\">NCT01882439<\/jats:ext-link>). Analyses included patients randomised to tofacitinib 5\/10\u2009mg two times a day or placebo, stratified by baseline BMI: &lt;25\u2009kg\/m<jats:sup>2<\/jats:sup>, \u226525\u2013&lt;30\u2009kg\/m<jats:sup>2<\/jats:sup>, \u226530\u2013&lt;35\u2009kg\/m<jats:sup>2<\/jats:sup> or \u226535\u2009kg\/m<jats:sup>2<\/jats:sup>. Endpoints (month 3): American College of Rheumatology (ACR20\/50\/70), Health Assessment Questionnaire-Disability Index (HAQ-DI) and Psoriasis Area and Severity Index (PASI) 75 response rates; dactylitis\/enthesitis resolution rates; changes from baseline Short Form-36 Health Survey version 2 (SF-36v2) Physical\/Mental Component Summary (PCS\/MCS) scores and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) total score. Safety was also reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Analysis included 710 patients; 43.8% were obese (BMI \u226530\u2009kg\/m<jats:sup>2<\/jats:sup>). Tofacitinib demonstrated higher efficacy response rates at month 3, compared with placebo, regardless of baseline BMI. Generally, ACR20\/50\/70 and HAQ-DI response rates, enthesitis resolution rates and changes from baseline in SF-36v2 PCS score and FACIT-F total score (month 3) were reduced in patients with baseline BMI \u226535\u2009kg\/m<jats:sup>2<\/jats:sup> versus patients with lower BMIs. Elevated alanine aminotransferase\/aspartate aminotransferase levels were reported in patients with baseline BMI \u226535\u2009kg\/m<jats:sup>2<\/jats:sup> receiving tofacitinib 5\u2009mg but not 10\u2009mg two times a day.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Tofacitinib demonstrated greater efficacy than placebo in patients with PsA, regardless of baseline BMI. For all treatment arms, reduced efficacy was observed in patients with baseline BMI \u226535\u2009kg\/m<jats:sup>2<\/jats:sup>. Safety was generally comparable across BMI categories, although the effect of tofacitinib on liver enzymes in patients with baseline BMI \u226535\u2009kg\/m<jats:sup>2<\/jats:sup> was inconclusive.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2020-001486","type":"journal-article","created":{"date-parts":[[2021,1,15]],"date-time":"2021-01-15T11:40:26Z","timestamp":1610710826000},"page":"e001486","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis"],"prefix":"10.1136","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01877668","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01882439","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02627768","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Jon T","family":"Giles","sequence":"first","affiliation":[{"name":"Department of Medicine\/Division of Rheumatology, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexis","family":"Ogdie","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J","family":"Gomez-Reino","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n del Instituto de Investigaci\u00f3n Sanitaria, Hospital Cl\u00ednico Universitario, Santiago de Compostela, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-9105","authenticated-orcid":false,"given":"Philip S","family":"Helliwell","sequence":"additional","affiliation":[{"name":"Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Germino","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Stockert","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Young","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Joseph","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Collegeville, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajiv","family":"Mundayat","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Graham","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2602-1219","authenticated-orcid":false,"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[{"name":"Department of Medicine\/Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,1,15]]},"reference":[{"key":"2025090312041336000_7.1.e001486.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2018.09.005"},{"key":"2025090312041336000_7.1.e001486.2","unstructured":"World Health Organization . Global health Observatory (GHO) data, 2020. Available: https:\/\/www.who.int\/gho\/ncd\/risk_factors\/bmi_text\/en\/ [Accessed 21 May 2020]."},{"key":"2025090312041336000_7.1.e001486.3","doi-asserted-by":"publisher","DOI":"10.1093\/icvts\/ivt178"},{"key":"2025090312041336000_7.1.e001486.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201299"},{"key":"2025090312041336000_7.1.e001486.5","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyu045"},{"key":"2025090312041336000_7.1.e001486.6","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64(Suppl 2)","author":"Gladman","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"2025090312041336000_7.1.e001486.7","doi-asserted-by":"publisher","DOI":"10.1177\/2040622315582354"},{"key":"2025090312041336000_7.1.e001486.8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22185"},{"key":"2025090312041336000_7.1.e001486.9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/acr.23094","article-title":"Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population-based study","volume":"69","author":"Jafri","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2025090312041336000_7.1.e001486.10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2217\/ijr.15.45","article-title":"Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis","volume":"10","author":"Ogdie","year":"2015","journal-title":"Int J Clin Rheumtol"},{"key":"2025090312041336000_7.1.e001486.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208337"},{"key":"2025090312041336000_7.1.e001486.12","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.13","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21711"},{"key":"2025090312041336000_7.1.e001486.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew326"},{"key":"2025090312041336000_7.1.e001486.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: a systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025090312041336000_7.1.e001486.16","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202812"},{"key":"2025090312041336000_7.1.e001486.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025090312041336000_7.1.e001486.18","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090312041336000_7.1.e001486.19","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-eular.3115","article-title":"SAT0293 Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of OPAL Balance, an open-label long-term extension study [abstract]","volume":"77","author":"Nash","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025090312041336000_7.1.e001486.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110546"},{"key":"2025090312041336000_7.1.e001486.21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i28.9330"},{"key":"2025090312041336000_7.1.e001486.22","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025090312041336000_7.1.e001486.23","first-page":"318","article-title":"The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis","volume":"34","author":"Hodge","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025090312041336000_7.1.e001486.24","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211708"},{"key":"2025090312041336000_7.1.e001486.25","doi-asserted-by":"publisher","DOI":"10.3390\/nu5041218"},{"key":"2025090312041336000_7.1.e001486.26","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.94944"},{"key":"2025090312041336000_7.1.e001486.27","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/2047-783X-15-S2-120","article-title":"Proinflammatory cytokines IL-6 and TNF-\u03b1 and the development of inflammation in obese subjects","volume":"15(Suppl 2)","author":"Popko","year":"2010","journal-title":"Eur J Med Res"},{"key":"2025090312041336000_7.1.e001486.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-009-0060-4"},{"key":"2025090312041336000_7.1.e001486.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2005.11.050"},{"key":"2025090312041336000_7.1.e001486.30","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-eular.5841","article-title":"OP0007 High body mass index (BMI) in psoriatic arthritis (PSA) is associated with higher disease activity in joints and skin, impaired quality of life and more disability: results from the PSABIO study [abstract]","volume":"78","author":"Siebert","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312041336000_7.1.e001486.31","first-page":"1640","article-title":"Effect of BMI on baricitinib efficacy: pooled analysis from two phase 3 rheumatoid arthritis clinical trials [abstract]","volume":"68","author":"Zerbini","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.32","first-page":"1518","article-title":"Baricitinib and tofacitinib in real life - does obesity impact response to Janus kinase inhibitor therapy in rheumatoid arthritis? [abstract]","volume":"70","author":"Mei\u00dfner","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.33","first-page":"2371","article-title":"The efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index [abstract]","volume":"69","author":"Dikranian","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.34","doi-asserted-by":"crossref","first-page":"S-1111","DOI":"10.1016\/S0016-5085(19)39739-2","article-title":"Tu1753 \u2013 analysis of the impact of body mass index on efficacy and safety in the tofacitinib Octave ulcerative colitis program","volume":"156","author":"Farraye","year":"2019","journal-title":"Gastroenterology"},{"key":"2025090312041336000_7.1.e001486.35","unstructured":"Pfizer Inc . Xeljanz\u00ae (tofacitinib): highlights of prescribing information, 2015. Available: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959 [Accessed 21 Nov 2020]."},{"key":"2025090312041336000_7.1.e001486.36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/jdv.13884","article-title":"Impact of immunogenicity on pharmacokinetics, efficacy and safety of adalimumab in adult patients with moderate to severe chronic plaque psoriasis","volume":"31","author":"Mostafa","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090312041336000_7.1.e001486.37","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1080\/19420862.2016.1216741","article-title":"The underlying inflammatory chronic disease influences infliximab pharmacokinetics","volume":"8","author":"Passot","year":"2016","journal-title":"MAbs"},{"key":"2025090312041336000_7.1.e001486.38","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.491"},{"key":"2025090312041336000_7.1.e001486.39","doi-asserted-by":"publisher","DOI":"10.2165\/11531280-000000000-00000"},{"key":"2025090312041336000_7.1.e001486.40","first-page":"1618","article-title":"Adipose tissue Inflammation in psoriatic arthritis: overexpression of a wide array of inflammatory mediators and associations with disease and treatment characteristics [abstract]","volume":"70","author":"Yun","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.41","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140673"},{"key":"2025090312041336000_7.1.e001486.42","doi-asserted-by":"crossref","DOI":"10.3390\/metabo10030107","article-title":"The interrelations between biological and targeted synthetic agents used in inflammatory joint diseases, and obesity or body composition","volume":"10","author":"Toussirot","year":"2020","journal-title":"Metabolites"},{"key":"2025090312041336000_7.1.e001486.43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/art.40726","article-title":"Special article: 2018 American College of Rheumatology\/National psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025090312041336000_7.1.e001486.44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025090312041336000_7.1.e001486.45","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.192644"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2020-001486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:04:20Z","timestamp":1756926260000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2020-001486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,15]]},"published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1136\/rmdopen-2020-001486"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2020-001486","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]}}}